Abstract The A-to-G mutation at nucleotide 3243 of the mitochondrial tRNA Leu(UUR) gene (mt.3243A>G) is associated with both diabetes mellitus and myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). Recently, this mutation was found in three diabetic subjects with progressive kidney disease, suggesting that it may be a contributing factor in the development of kidney disease in patients with diabetes. The aim of this study was to evaluate the contribution of this mutation to the development of end stage renal disease (ESRD) in patients with diabetes. The study group consisted of 135 patients with diabetes and ESRD. The control group consisted of 92 non-diabetic subjects with ESRD who were receiving hemodialysis. The mt.3243A>G mutation was detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). We found the mt.3243A>G mutation in eight patients (8/135; 5.9%), all of whom were initially diagnosed with type II diabetes. Five of the eight patients were subsequently also diagnosed with MELAS. We did not find the mutation in any of the 92 nondiabetic subjects with ESRD. The prevalence of this mutation was 6.5-fold higher in patients with diabetes and ESRD than in those with diabetes alone (8/135 vs 5/550, respectively; 2 = 13.704; P = 0.0002). The mt.3243A>G mutation may be a contributing genetic factor in the development of ESRD in Japanese patients with diabetes.
Introduction
Mutations in the maternally inherited mitochondrial genome have been found to be associated with a subtype of diabetes mellitus designated maternally inherited diabetes and deafness (MIDD) (van den Ouweland et al. 1992) . The most common mitochondrial mutation found in patients with diabetes is an A-to-G transition at nucleotide 3243 of the mitochondrial tRNA Leu(UUR) gene (mt.3243AϾG). This mutation was found in approximately 0.9% of Japanese diabetic patients (Otabe et al. 1994 ). The mt.3243AϾG mutation is also the cause of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) (Ciafaloni et al. 1992 ) and has been found in patients with progressive kidney disease, diabetes, and deafness (Jansen et al. 1997 ). In addition, we have seen several diabetic patients with this mutation who showed evidence of proteinuria prior to the diagnosis of diabetes mellitus or diabetic retinopathy, suggesting that it may be a contributing factor in the development of kidney disease, in addition to diabetic nephropathy per se (N.I., unpublished observation). Based on these findings, we screened a group of diabetic subjects who had end stage renal disease (ESRD), as well as a group of patients with nondiabetic ESRD, for the mt.3243AϾG mutation, in order determine the prevalence and contribution of this mutation to the development of kidney disease in Japanese patients.
Subjects and methods

Subjects
We studied two groups of subjects. The first group consisted of 135 unrelated Japanese patients (M/F, 91/44) with diabetes mellitus (type I/type II, 11/124) and ESRD. All had been treated for diabetes and had started dialysis treatment at the Diabetes Center of Tokyo Women's Medical University between January 1991 and December 1998. The age at diagnosis of diabetes in this group was 36.2 Ϯ 14.1 years (mean Ϯ SD) and the duration of diabetes was 16.8 Ϯ 7.6 years. The age at the start of dialysis treatment was 52.7 Ϯ 12.7 years. The second group consisted of 92 patients with ESRD, but without diabetes, who were receiving hemodialysis treatment at the hemodialysis unit of the Department of Nephrology, Tokyo Women's Medical University. The clinical features of the diabetic subjects were obtained retrospectively through their medical records. This study was approved by the Institutional Review Board of Tokyo Women's Medical University and was carried out in accordance with the principles of the Declaration of Helsinki II. Informed consent was obtained from all subjects.
Detection of mt.3243AϾG mutation Genomic DNA was prepared from peripheral blood, using a standard procedure. The presence of the mt.3243AϾG mutation was identified, using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. An 854-bp fragment of mitochondrial DNA was amplified, using PCR and primers 5Ј-CACTGTTCCTTAAATAGGG-3Ј (nt 2603-2622), and 5Ј-AGCGAAGGGTTGTAGTAGCC-3Ј (nt 3437-3456) in the presence of [α-32 P]-dCTP. PCR was performed in a 25-µl volume containing 25 mM Tris-HCl, pH 8.0, 50 mM KCl, 1.5 mM MgCl 2 , 5 mM dNTPs, 10 pmol of each primer, 0.2 U Taq DNA Polymerase (Amersham, Little Chalfont, UK), and 200 ng of genomic DNA. The PCR consisted of 30 cycles of denaturation at 94°C for 1 min, annealing at 60°C for 1 min, and extension at 72°C for 2 min, with a final extension at 72°C for 10 min. A 1.0-µl aliquot of the reaction was digested in a 20-µl volume with 20 U of ApaI at 37°C for 2 h. The PCR products were separated by electrophoresis on a 5% nondenaturing polyacrylamide gel and visualized by autoradiography. The mt.3243AϾG mutation created a site for the enzyme ApaI and, with the primers described above, the A-allele gave a fragment of 854 bp and the Gallele, fragments of 641 and 213 bp.
The tissue distribution of the mt.3243AϾG mutation was measured in DNA prepared from the postmortem tissues of patient 5 (see Table 2 ), who died at 47 years of age. The degree of heteroplasmy was assessed using an image analyzer.
Statistical analysis
Student's t-test and the 2 test were used for statistical comparisons, and P Ͻ 0.05 was considered significant.
Results
The mt.3243AϾG mutation was found in heteroplasmic form in 8 of the 135 patients with diabetes and ESRD, but in none of the 92 patients with ESRD alone. Each of the subjects with the mt.3243AϾG mutation had initially been diagnosed with type II diabetes. The clinical features of patients with ESRD and diabetes, with and without the mt.3243AϾG mutation, are summarized in Table 1 . The mean ages at the time of the study, at the diagnosis of diabetes, and at the start of dialysis treatment were significantly lower in the group of patients with the mutation. There were no significant differences between the two groups with regard to the duration of diabetes or the length of time between age at diagnosis of diabetes and start of dialysis treatment. The mean time interval between the diagnosis of diabetes and the start of dialysis in the eight patients with the mutation was 17.5 Ϯ 7.3 years (range, 4-23 years). The subjects with the mutation were, on average, shorter and weighed less than those without the mutation.
The specific clinical features of the eight patients with the mt.3243AϾG mutation are shown in Table 2 . Proteinuria preceded the diagnosis of diabetes in two patients. Deafness was present in all eight patients. Five patients had undergone skeletal muscle biopsy to examine the cause of muscle atrophy that became prominent during the course of follow-up. Gomori-trichrome staining showed the presence of ragged red fibers in the biopsy samples of all five patients. Brain computed tomography/ magnetic resonance imaging (CT/MRI) scanning in six patients revealed the following findings either singly or in combination: calcium deposition in the basal ganglia, cerebral/cerebellar atrophy, or cerebral infarction. In addition, five patients had a history of stroke-like episodes, such as syncope or severe headaches, during the course of treatment. Five patients (subjects 1, 2, 5, 7, and 8) had a history of maternal diabetes or impaired glucose tolerance (IGT), and four patients (subjects 1, 3, 4, and 8) had a family history of renal dysfunction (Fig. 1) . The younger sister of subject 1 died of acute renal failure, the details of which were not available, and the mother had diabetes and deafness, but had not received hemodialysis treatment. The brother of subject 3 had deafness, diabetes, and moderate kidney dysfunction. His father also had ESRD. His mother had died of a myocardial infarction, but was not known to have had either diabetes or renal dysfunction. The mother of subject 4 had ESRD, and one of his sisters had diabetes mellitus, MELAS, and ESRD. The maternal aunt and mother of subject 8 had diabetes with deafness. His older brother, who is positive for this mutation, also has diabetes, deafness, and renal dysfunction.
We were able to carry out histological studies on kidney tissue from one of these eight patients. This female patient (subject 5) died of multiorgan failure after sustaining a bone fracture; the resulting rhabdomyolysis had led to acute-onchronic renal failure. The kidneys showed scattered nodular diabetic glomerulosclerosis, compatible with classical diabetic nephropathy. Some tubules contained densely eosinophilic hyaline casts that were positive for myoglobin. We examined a number of tissues, including kidney, pancreas, and cerebrum, for the presence of the mt.3243AϾG mutation, and all showed heteroplasmy for this mutation. The degree of heteroplasmy was greater than 50% in the kidney and cerebrum, and it was 40% in the pancreas (data not shown).
Discussion
We identified the mt.3243AϾG mutation in 8 of 135 (5.9%) subjects with ESRD and diabetes mellitus (type I and type II), and in none of 92 nondiabetic subjects with ESRD alone. Each of the patients with the mt.3243AϾG mutation was initially diagnosed with type II diabetes. Hearing loss was observed, but additional neurological manifestations were not evident at presentation. Five of these patients subsequently exhibited clinical characteristics of MELAS, although none of these features were evident when they first came to clinical attention. The years at which hemodialysis was started in the eight carriers of the mutation ranged from 1992 to 1998: two patients started in 1992, one started in 1993, two started in 1994, one started in 1995, one started in 1996, none started in 1997, and one started in 1998.
The mt.3243AϾG mutation has been reported to have a prevalence of 0.9% (5/550) in a randomly selected sample (Otabe et al. 1994) . Thus, the mt.3243AϾG mutation has a 6.5-fold risk of ESRD (8/135 vs 5/550, respectively; 2 ϭ 13.704; P ϭ 0.0002). Jansen et al. (1997) identified four individuals with this mutation from three families who suffered progressive kidney disease in association with diabetes and hearing loss, and emphasized the existence of a form of kidney disease that is characterized by the presence of this mutation. Our results are consistent with their observation, and support the notion that the mt.3243AϾG mutation is one of the genetic factors involved in the development of kidney dysfunction in patients with diabetes. However, our results differ from those of Yamagata et al. (2000) , who found the mt.3243AϾG mutation in only 1 of 132 (0.8%) Japanese patients with diabetes and ESRD, a value similar to that in the general diabetic population in Japan (Otabe et al. 1994) . The reason for the difference between the results of our study and that of Yamagata et al. is not known.
All eight patients that we identified with the mt.3243AϾG mutation had typical features of MIDD, such as lean body and short stature with deafness. The etiology of kidney dysfunction in these eight patients was clinically diagnosed as diabetic nephropathy, because all of them had proliferative retinopathy. It was not possible to obtain the histological findings from these patients, because they had already developed ESRD. Thus, it is not clear whether the diabetic nephropathy in these patients was exacerbated in association with the mutation, or whether another form of kidney disease was involved. Five of the eight patients have been diagnosed with MELAS, but at present, the remaining three patients have not been diagnosed with this condition.
The mt.3243AϾG mutation has been found in 80% of patients with MELAS and is the most common cause of this condition (Goto et al. 1990 ). However, there is no report in the literature regarding the proportion of diabetic patients with the mt.3243AϾG mutation who have MELAS. There is also little information about kidney involvement in patients with MELAS (Brown and Wallace 1994; Ciafaloni et al. 1992; Goto et al., 1990 Goto et al., , 1992 Koo et al. 1993) . The renal dysfunction in MELAS has been reported to share features with renal tubular acidosis, Bartter's syndrome, and Fanconi syndrome, with focal glomerulosclerosis being a typical histological finding in these patients (Hsieh et al. 1996) . Our results, and those of Jansen et al. (1997) , indicate the need for further study of the mt.3243AϾG mutation in diabetic patients with ESRD.
In conclusion, we suggest that the mt.3243AϾG mutation may be a contributing genetic factor in the development of ESRD in Japanese patients with diabetes mellitus.
